In this context, pre-clinical models have also shown that intratumoral administration of non-adjuvanted influenza vaccine delayed tumor growth and boosted the response to anti-PD-1 immunotherapy, mainly by recruiting and activating cross-presenting dendritic cells and CD8+ T cells (177). This evidence concerns the gene CD8A and neoplasm.